Triple threat: new combo aims to boost kidney cancer treatment
NCT ID NCT06708949
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 34 times
Summary
This study tests whether adding a third drug (relatlimab) to a standard two-drug combination (nivolumab and ipilimumab) works better for advanced kidney cancer that hasn't been treated before. About 15 adults with stage IV clear cell kidney cancer will receive either the three-drug or two-drug regimen. The main goal is to check safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA, CLEAR CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
Contact Email: •••••@•••••
Contact
-
Penn Medicine Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.